PYC Therapeutics, a clinical-stage biotechnology company pioneering a new generation of RNA therapeutics, has announced plans to work with Google Cloud and other specialised partners to create a new generation of medicines.
The ASX-listed business will use its own proprietary data sets in the project which will be hosted on Google Cloud's AI platform and designed to predict optimal sequences and structures of peptides with the ability to deliver precision medicine cargoes to specific cells within the body.
According to a release on the ASX, the specialised partners have skill sets relevant to the implementation of the project, and will pay $4.5 million up front to PYC for the benefit of accessing its proprietary data sets and capabilities.
The release said that Google would also benefit from the newly formed partnership "through retention of the right to publish the process used to design, host and execute the machine learning models which use AlphaFold, its successor technologies, and Google Cloud's AI platform". DF
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jan 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jan 24
